1 / 79

HEMATOLOGIC EMERGENCIES

HEMATOLOGIC EMERGENCIES. Jason Mitchell Michael Szava-Kovats Joe Vipond May 17, 2012. HEMOSTASIS. HEMOSTASIS. HEMOSTASIS. HEMOSTASIS. HEMOSTASIS. PTT. PT/INR. CASE. 30 yo M Tooth extraction Consistent oozing Stable DDx? Investigations?. CASE. 63. 135. 140. 111. 130. 7.

yuki
Download Presentation

HEMATOLOGIC EMERGENCIES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HEMATOLOGIC EMERGENCIES Jason Mitchell Michael Szava-Kovats Joe Vipond May 17, 2012

  2. HEMOSTASIS

  3. HEMOSTASIS

  4. HEMOSTASIS

  5. HEMOSTASIS

  6. HEMOSTASIS PTT PT/INR

  7. CASE • 30 yo M • Tooth extraction • Consistent oozing • Stable • DDx? • Investigations?

  8. CASE 63 135 140 111 130 7 4.0 24 INR: 0.9 PTT: 54

  9. von WILLEBRAND DISEASE

  10. von WILLEBRAND DISEASE • THREE TYPES • Type I: Partial quantitative deficiency vWF • AD, Most common (75%) • Type II: Abnormally functioning vWF • AD or AR, Subtypes: IIA, IIB, IIM, IIN • Type III: Total quantitative deficiency vWF • AR, Leads to severe bleeding

  11. von WILLEBRAND DISEASE • INVESTIGATIONS • Plasma vWF:Ag Decreased • Plasma vWF Activity Decreased • FVIII Levels Decreased

  12. von WILLEBRAND DISEASE • MANAGEMENT OPTIONS • Standard measures • DDAVP • vWF Replacement

  13. von WILLEBRAND DISEASE

  14. von WILLEBRAND DISEASE • DESMOPRESSIN (DDAVP/OCTOSTIM) • 0.3 μg/kg IV (MAX 20 μg) SC/IV over 20-30 minutes

  15. von WILLEBRAND DISEASE • vWF REPLACEMENT • Humate P 60 – 80 Units/kg IV

  16. von WILLEBRAND DISEASE • ?r-vWF • Some promising results in animal studies • Currently in phase III human trials.

  17. HEMOSTASIS

  18. CASE • 51 yo M • Fall down 3 stairs, Stable • No LOC, no neuro deficits • No neck pain • C/O R knee pain/swelling • Hemophiliac

  19. HEMOPHILIA • Management priorities?

  20. HEMOPHILIA • HEMOPHILIA A • Factor VIII Deficiency • X-linked recessive • 1:5-10 000 males • HEMOPHILIA B • Factor IX Deficiency • X-linked recessive • 1:25-30 000 males

  21. HEMOPHILIA • Initial Investigations?

  22. HEMOPHILIA 76 105 138 101 115 13 4.1 19 INR: 0.9 PTT: 76

  23. HEMOPHILIA • INVESTIGATIONS • Factor VIII Level Decreased • Factor IX Level Decreased

  24. HEMOPHILIA • MANAGEMENT Depends on: Clotting factor activity level Location of bleed

  25. HEMOPHILIA

  26. HEMOPHILIA • BLEEDING LOCATION LIFE/LIMB THREATENING BLEED MODERATE/MINOR BLEED

  27. HEMOPHILIA • LIFE/LIMB THREATENING BLEED

  28. HEMOPHILIA • MILD/MODERATE BLEED

  29. HEMOPHILIA • MANAGEMENT OPTIONS • Cryoprecipitate • FFP • DDAVP • rFVIII / rFIX • Antifibrinolytics

  30. HEMOPHILIA • CRYOPRECIPITATE • FVIII, vWF, Fibrinogen • 2 bags / 10 kg • Not first line therapy – use if rFVIII not available • FFP • All coagulation factors • Not ideal • Need to double plasma volume level

  31. HEMOPHILIA • DESMOPRESSIN (DDAVP/OCTOSTIM) • 0.3 μg/kg IV (MAX 20 μg) SC/IV over 20-30 minutes

  32. HEMOPHILIA • rFVIII (KOGENATE) • MILD/MODERATE • 30 U/kg • SEVERE • 50 U/kg • rFIX (BeneFIX) • MILD/MODERATE • 50 U/kg > 15 • 70 U/kg < 15 • SEVERE • 120 U/kg > 15 • 160 U/kg < 15

  33. HEMOPHILIA • WHEN IN DOUBT, TREAT AS SEVERE BLEED!

  34. HEMOPHILIA • ANTIFIBRINOLYTICS • Tranexamic Acid • Epsilon Aminocaproic Acid

  35. HEMOPHILIA PLASMINOGEN

  36. HEMOPHILIA • ANTIFIBRINOLYTICS • 25 mg/kg PO TID 1-7 days

  37. HEMOPHILIA • THERAPEUTIC ENDPOINTS • Bleeding cessation • Symptom resolution • Correction of PTT • Raised factor activity level

  38. BACK TO CASE • 51 yo M • Fell down three stairs • Stable • R knee hemarthrosis • HEMOPHILIA A

  39. HEMOPHILIA • What type of bleed?

  40. HEMOPHILIA A

  41. HEMOPHILIA A • Management?

  42. HEMOPHILIA

  43. HEMOPHILIA • Why is the patient not responding?

  44. HEMOPHILIA • INHIBITORS • Formation of anti-factor antibodies (IgG) • 1/3 severe Hemophilia A; 1/50 mild/moderate Hemophelia A • 1/100 Hemophelia B • Can be transient

  45. HEMOPHILIA • INHIBITOR MANAGEMENT • aPCC (FEIBA) • rFVII (NIASTASE) • 90 μg/kg q2h x 3 • or until bleeding stops

  46. HEMOPHILIA A

More Related